AUTL Autolus Therapeutics plc

Healthcare [ 3/11 ] | Biotechnology [ 34/154 ]

GB | NASDAQ | Stock

Price: $2.03

Decreased by -1.93%
Dollar Volume: 1.07 M
ADR%: 8.27
Earnings Report Date (estimate): Nov 3, 22 (-0.4)

Market Cap.: 351.31 M
Shares Float: 42.79 M
Shares Outstanding: 173.06 M

Beta: 1.56
Price / Earnings: -1.10
BPR: 17.99

20D Range: 1.77 2.15
50D Range: 1.60 3.53
200D Range: 1.60 3.79

Quarterly Earnings
Annual Earnings

Reported Date	EPSChange YoY	EstimateSurprise
Nov 3, 22	-0.47 Increased by 0.00%	-0.46 Decreased by -2.17%
Aug 4, 22	-0.46 Increased by +2.13%	-0.42 Decreased by -9.52%
May 5, 22	-0.41 Increased by +22.64%	-0.48 Increased by +14.58%
Mar 10, 22	-0.51 Increased by +38.55%	-0.46 Decreased by -10.87%
Nov 3, 21	-0.47 Increased by +34.72%	-0.51 Increased by +7.84%
Aug 5, 21	-0.47 Increased by +24.19%	-0.50 Increased by +6.00%
May 6, 21	-0.53 Increased by +11.67%	-0.60 Increased by +11.67%
Mar 4, 21	-0.83 Increased by +1.19%	-0.77 Decreased by -7.79%

Quarterly Financials
Annual Financials

Fiscal ending date	RevenueChange YoY	IncomeChange YoY	ProfitChange YoY
Sep 30, 22	2.37 M Increased by +N/A%	-42.77 M Decreased by -25.82%	Decreased by -1.81 K% Decreased by N/A%
Jun 30, 22	0.00 Decreased by -100.00%	-42.06 M Decreased by -26.79%	Decreased by N/A% Decreased by N/A%
Mar 31, 22	0.00 Decreased by -100.00%	-37.06 M Decreased by -11.41%	Decreased by N/A% Decreased by N/A%
Dec 31, 21	823.00 K Increased by +N/A%	-41.67 M Increased by +2.79%	Decreased by -5.06 K% Decreased by N/A%
Sep 30, 21	0.00 Decreased by -100.00%	-33.99 M Increased by +8.91%	Decreased by N/A% Decreased by N/A%
Jun 30, 21	1.51 M Increased by +414.33%	-33.17 M Decreased by -3.52%	Decreased by -2.20 K% Increased by +79.87%
Mar 31, 21	269.00 K Decreased by -20.41%	-33.27 M Decreased by -11.36%	Decreased by -12.37 K% Decreased by -39.92%
Dec 31, 20	0.00 Decreased by -100.00%	-42.86 M Decreased by -4.68%	Decreased by N/A% Decreased by N/A%

Top 20 ETF Stock Exposure
Top 20 Institutional Holders
Top 20 Mutual Fund Holders

Rank	ETF	Shares	Market Value	Weight % in ETF

DAILY

WEEKLY

MONTHLY

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.